Lung stereotactic body radiotherapy (SBRT) is the standard of care for patients with inoperable early-stage non-small cell lung cancer (NSCLC), who frequently have significant comorbidities. There is no standardised method to predict how age and comorbidities influence SBRT efficacy or toxicity. The Charlson Comorbidity Index (CCI) and its age-adjusted variant (aCCI) have been proposed as prognostic tools, though their predictive value remains uncertain. This study assessed the prognostic relevance of the CCI and aCCI in patients undergoing SBRT for early-stage NSCLC. This retrospective single-institution study included patients with NSCLC treated with SBRT between January 2010 and December 2023. Patients receiving standard SBRT dose-fractionation for peripheral, central, and ultracentral tumours were eligible. CCI and aCCI scores were calculated for all patients. The primary objective was to compare overall survival (OS) between patients with low ( 2) was not associated with worse OS (univariate: HR 0.97, 95% CI: 0.43–2.16, p = 0.93; multivariate: HR 0.16, 95% CI: 0.03–0.92, p = 0.04). High aCCI (> 6) was also not significantly associated with OS (HR 1.02, 95% CI: 0.43–2.38, p = 0.97). Patients with peripheral tumours had a significantly higher risk of death than those with central tumours (HR 4.7 × 10⁹, 95% CI: 1.1 × 10⁹–2.01 × 10¹⁰, p < 0.001). No other variables significantly influenced survival. SBRT was well tolerated, with no grade 4–5 toxicities or treatment-related deaths. The CCI and aCCI did not predict overall or disease-specific survival in patients treated with SBRT for early-stage NSCLC. These findings suggest that current comorbidity indices may be inadequate in this population and highlight the need for improved prognostic tools to guide treatment decisions.
Jayamanne et al. (Fri,) studied this question.